Love this point, hits home: “If the clinical wall is the problem, the right response is to generate data that predict clinical failure earlier: human-relevant immunogenicity, ADMET, and perturbation responses in systems that actually resemble the patient. Those are harder projections, at higher organizational layers, exactly the ones the current data ignores. And it is an argument for all the applications of biological understanding that have no clinical trial at all (surveillance, manufacturing, environmental biology), where the clinical wall does not exist, and the data gap is just as real.”